{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T03:12:03Z","timestamp":1768446723886,"version":"3.49.0"},"reference-count":40,"publisher":"Informa UK Limited","issue":"19","license":[{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Millennium Pharmaceuticals, Inc., Cambridge, MA, United States, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.2217\/fon-2020-1225","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T09:10:32Z","timestamp":1616749832000},"page":"2499-2512","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":21,"title":["Ixazomib-Lenalidomide-Dexamethasone in Routine Clinical Practice: Effectiveness in Relapsed\/refractory Multiple Myeloma"],"prefix":"10.1080","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6955-6267","authenticated-orcid":false,"given":"Roman","family":"H\u00e1jek","sequence":"first","affiliation":[{"name":"University Hospital Ostrava & Faculty of Medicine, University of Ostrava, Ostrava, 703 00, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji\u0159\u00ed","family":"Mina\u0159\u00edk","sequence":"additional","affiliation":[{"name":"Palacky University & University Hospital Olomouc, Olomouc, 771 47, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Straub","sequence":"additional","affiliation":[{"name":"General Teaching Hospital, Prague, 128 08, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lud\u011bk","family":"Pour","sequence":"additional","affiliation":[{"name":"University Hospital, Brno, 625 00, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Jungova","sequence":"additional","affiliation":[{"name":"Faculty Hospital Pilsen, Pilsen, 301 00, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesus G","family":"Berdeja","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute, Nashville, TN37203, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8130-5209","authenticated-orcid":false,"given":"Mario","family":"Boccadoro","sequence":"additional","affiliation":[{"name":"University of Torino, Torino, 10124, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucie","family":"Brozova","sequence":"additional","affiliation":[{"name":"Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[{"name":"Alfred Health-Monash University, Melbourne, 3004, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frits","family":"van Rhee","sequence":"additional","affiliation":[{"name":"University of Arkansas for Medical Sciences, Little Rock, AR72205, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Vela-Ojeda","sequence":"additional","affiliation":[{"name":"UMAE Especialidades Centro Medico La Raza IMSS, Ciudad de M\u00e9xico, 02990, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A","family":"Thompson","sequence":"additional","affiliation":[{"name":"Advocate Aurora Research Institute, Advocate Aurora Health, Milwaukee, WI53227, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafat","family":"Abonour","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine, Indianapolis, IN46202, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, New York, NY10029, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon","family":"Cook","sequence":"additional","affiliation":[{"name":"Leeds Teaching Hospital, Leeds, LS1 3EX, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3405-5937","authenticated-orcid":false,"given":"Caitlin L","family":"Costello","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, University of California San Diego, La Jolla, CA92037, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faith E","family":"Davies","sequence":"additional","affiliation":[{"name":"Perlmutter Cancer Center, NYU Langone, New York, NY10016, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vania T M","family":"Hungria","sequence":"additional","affiliation":[{"name":"Clinica S\u00e3o Germano & Santa Casa Medical School, S\u00e3o Paulo, 04537-081, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans C","family":"Lee","sequence":"additional","affiliation":[{"name":"M.D. Anderson Cancer Center, Houston, TX77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[{"name":"P\u00f4le R\u00e9gional de Canc\u00e9rologie, CHU de Poitiers, Poitiers, 86000, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7535-3861","authenticated-orcid":false,"given":"Noemi","family":"Puig","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC (CB16\/12\/00233), Salamanca, 37007, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M","family":"Rifkin","sequence":"additional","affiliation":[{"name":"Rocky Mountain Cancer Centers US Oncology Research, Denver, CO80218, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-1422","authenticated-orcid":false,"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[{"name":"National & Kapodistrian University of Athens, School of Medicine, Athens, 115 27, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad Z","family":"Usmani","sequence":"additional","affiliation":[{"name":"Levine Cancer Institute, Charlotte, NC115 27, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja C","family":"Weisel","sequence":"additional","affiliation":[{"name":"University Medical Center Hamburg-Eppendorf, Hamburg, 20251, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A","family":"Zonder","sequence":"additional","affiliation":[{"name":"Barbara Ann Karmanos Cancer Institute \/ Wayne State University School of Medicine, Detroit, MI48201, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magda","family":"Ba\u0159inov\u00e1","sequence":"additional","affiliation":[{"name":"Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maty\u00e1\u0161","family":"Kuhn","sequence":"additional","affiliation":[{"name":"Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji\u0159\u00ed","family":"\u0160ilar","sequence":"additional","affiliation":[{"name":"Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lenka","family":"\u010c\u00e1pkov\u00e1","sequence":"additional","affiliation":[{"name":"Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenny","family":"Galvez","sequence":"additional","affiliation":[{"name":"Hospital Pablo Tob\u00f3n Uribe, Medellin, 11001, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Lu","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital, National Clinical Research Center for Hematologic Disease, Beijing, 100044, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Elliott","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., Cambridge, MA02139, USA, a wholly owned subsidiary of\rTakeda Pharmaceutical Company Limited"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn Marie","family":"Stull","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., Cambridge, MA02139, USA, a wholly owned subsidiary of\rTakeda Pharmaceutical Company Limited"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaili","family":"Ren","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., Cambridge, MA02139, USA, a wholly owned subsidiary of\rTakeda Pharmaceutical Company Limited"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladim\u00edr","family":"Maisnar","sequence":"additional","affiliation":[{"name":"Charles University Hospital & Faculty of Medicine, Hradec Kr\u00e1lov\u00e9, 121 08, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,3,26]]},"reference":[{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0141-0"},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2020.1729734"},{"key":"e_1_3_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.06.013"},{"key":"e_1_3_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-125749"},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.625"},{"key":"e_1_3_8_8_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2016.1170828"},{"key":"e_1_3_8_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017010512"},{"key":"e_1_3_8_10_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0013"},{"key":"e_1_3_8_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0702-1"},{"key":"e_1_3_8_12_1","unstructured":"NINLARO US prescribing information (2016). Updated. (2016). https:\/\/www.ninlaro.com\/prescribing-information.pdf"},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282"},{"key":"e_1_3_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-03985-9"},{"issue":"2","key":"e_1_3_8_15_1","first-page":"786","article-title":"Real world use of ixazomib with lenalidomide and dexamethasone for patients with relapsed and relapsed refractory multiple myeloma","volume":"102","author":"Ziff M","year":"2017","unstructured":"Ziff M , CheesemanS, KyriakouCet al. Real world use of ixazomib with lenalidomide and dexamethasone for patients with relapsed and relapsed refractory multiple myeloma. Haematologica102(Suppl. 2), 786\u2013787 (2017).","journal-title":"Haematologica"},{"issue":"2","key":"e_1_3_8_16_1","first-page":"511","article-title":"\u201cReal-world\u201d data on the efficacy and safety of ixazomib in combination with lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: a study of the Greek Myeloma Study Group","volume":"102","author":"Terpos E","year":"2017","unstructured":"Terpos E , KatodritouE, KotsopoulouM, AlE. \u201cReal-world\u201d data on the efficacy and safety of ixazomib in combination with lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: a study of the Greek Myeloma Study Group. Haematologica102(Suppl. 2), 511\u2013512 (2017).","journal-title":"Haematologica"},{"key":"e_1_3_8_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-03981-z"},{"key":"e_1_3_8_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-019-00607-2"},{"key":"e_1_3_8_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07732-1"},{"key":"e_1_3_8_20_1","doi-asserted-by":"publisher","DOI":"10.14735\/amko20172S43"},{"key":"e_1_3_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_3_8_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.1663"},{"key":"e_1_3_8_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000563952.08050.24"},{"issue":"2","key":"e_1_3_8_24_1","first-page":"520","article-title":"The use of carfilzomib and bortezomib in routine clinical, practice: results from PREAMBLE, an ongoing, observational cohort study in multiple myeloma","volume":"102","author":"Durie B","year":"2017","unstructured":"Durie B , CookG, GoldschmidtH, KuterD, ZyczynskiT. The use of carfilzomib and bortezomib in routine clinical, practice: results from PREAMBLE, an ongoing, observational cohort study in multiple myeloma. Haematologica102(Suppl. 2), 520 (2017).","journal-title":"Haematologica"},{"key":"e_1_3_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.04.003"},{"key":"e_1_3_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.03.147"},{"key":"e_1_3_8_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2016.1195254"},{"issue":"1","key":"e_1_3_8_28_1","first-page":"3093","article-title":"Evaluation of efficacy outcomes among relapsed\/refractory multiple myeloma treated patients in a real-world setting","volume":"130","author":"Nooka A","year":"2017","unstructured":"Nooka A , VoorheesPM, KumarSKet al. Evaluation of efficacy outcomes among relapsed\/refractory multiple myeloma treated patients in a real-world setting. Blood130(Suppl. 1), 3093 (2017).","journal-title":"Blood"},{"key":"e_1_3_8_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620718816699"},{"issue":"1","key":"e_1_3_8_30_1","first-page":"5405","article-title":"Real-world data in relapsed refractory myeloma patients treated with carfilzomib, a multicenter Turkish experience","volume":"130","author":"Sevindik OG","year":"2017","unstructured":"Sevindik OG , PehlivanM, TuglularTFet al. Real-world data in relapsed refractory myeloma patients treated with carfilzomib, a multicenter Turkish experience. Blood130(Suppl. 1), 5405 (2017).","journal-title":"Blood"},{"key":"e_1_3_8_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.3337.3337"},{"key":"e_1_3_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.07.583"},{"key":"e_1_3_8_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8060877"},{"key":"e_1_3_8_34_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2017.23.2.236"},{"key":"e_1_3_8_35_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.067793"},{"key":"e_1_3_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00464-7"},{"key":"e_1_3_8_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411321"},{"key":"e_1_3_8_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136519"},{"key":"e_1_3_8_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-133807"},{"key":"e_1_3_8_40_1","doi-asserted-by":"publisher","DOI":"10.4065\/79.7.867"},{"key":"e_1_3_8_41_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.170118"},{"key":"e_1_3_8_42_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0724"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2020-1225","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T18:47:44Z","timestamp":1726598864000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2020-1225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,26]]},"references-count":40,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.2217\/fon-2020-1225"],"URL":"https:\/\/doi.org\/10.2217\/fon-2020-1225","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-12-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}